ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: USP47 knockdown significantly inhibited both BCR-ABL-induced CML in mice and BCR-ABLT315I-induced CML, which are known to confer Imatinib and second-generation TKI resistance10.